Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.

@article{Pollack2010MismatchRD,
  title={Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.},
  author={Ian F Pollack and Ronald L. Hamilton and Robert William Sobol and Marina N. Nikiforova and Yuri E Nikiforov and Maureen A. Lyons-Weiler and William A Laframboise and Peter C. Burger and Daniel J. Brat and Marc K. Rosenblum and Floyd Gilles and Allan J. Yates and Tianni Zhou and Kenneth J. Cohen and Jonathan L Finlay and Regina I. Jakacki},
  journal={Pediatric blood & cancer},
  year={2010},
  volume={55 6},
  pages={1066-71}
}
BACKGROUND Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O(6)-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent… CONTINUE READING
14 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Molecular predictors of outcome in childhood malignant gliomas: The Children’s Oncology Group experience

  • IF Pollack, RL Hamilton, J Burnham
  • Neuro-Oncology
  • 2007
2 Excerpts

Should temozolomide be the standard of care for children with newly diagnosed high-grade gliomas? Results of the Children’s Oncology Group ACNS0126 study

  • KJ Cohen, R Heideman, T Zhou
  • 2007

Similar Papers

Loading similar papers…